Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study

OBJECTIVE: The objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a component of Helicobacter pylori eradication therapy. DESIGN: A randomised, double-blind, multicentre, parallel-group study was conducted to veri...

Descripción completa

Detalles Bibliográficos
Autores principales: Murakami, Kazunari, Sakurai, Yuuichi, Shiino, Madoka, Funao, Nobuo, Nishimura, Akira, Asaka, Masahiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Helicobacter Pylori
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036253/
https://www.ncbi.nlm.nih.gov/pubmed/26935876
http://dx.doi.org/10.1136/gutjnl-2015-311304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036253/
https://www.ncbi.nlm.nih.gov/pubmed/26935876
http://dx.doi.org/10.1136/gutjnl-2015-311304

Ejemplares similares